Mercado mundial de vacunas inactivadas: tendencias de la industria y pronóstico hasta 2030

Análisis y tamaño del mercado de vacunas inactivadas

Se prevé que la amplia introducción de nuevas vacunas inactivadas tras la finalización de los estudios clínicos aumente el crecimiento del mercado durante el período de pronóstico. El aumento de los casos de enfermedades infecciosas impulsa el mercado de vacunas inactivadas. La creciente frecuencia de varias infecciones virales y bacterianas a nivel mundial ha impulsado la demanda de vacunas inactivadas que impulsarán el mercado. Se esperaba que los brotes anuales de gripe causaran entre 3 y 5 millones de casos de gripe grave y entre 290.000 y 650.000 muertes en 2018, según el informe de la Organización Mundial de la Salud (OMS).

 Data Bridge Market Research analiza la tasa de crecimiento del mercado de vacunas inactivadas en el período de pronóstico 2023-2030. La CAGR esperada del mercado de vacunas inactivadas tiende a rondar el 7,10% en el período de pronóstico mencionado. El mercado está valorado en USD 40.763,4 millones en 2022 y crecerá hasta USD 70.564,48 millones para 2030. Además de los conocimientos del mercado, como el valor de mercado, la tasa de crecimiento, los segmentos del mercado, la cobertura geográfica, los actores del mercado y el escenario del mercado, el informe de mercado curado por el equipo de Data Bridge Market Research también incluye un análisis profundo de expertos, epidemiología del paciente, análisis de la cartera, análisis de precios y marco regulatorio.

Alcance y segmentación del mercado de vacunas inactivadas

Market Definition

Inactivated vaccines are grown in controlled culture conditions and are killed to decrease their infectivity. Inactivated vaccines are found to be not that much effective compared tolive-attenuated vaccines. Multiple booster shots and immunologic adjuvants are essential to provide an effective immune response against the diseases. Inactivated vaccines include whole-cell inactivated vaccines such as polio, hepatitis A, and rabies vaccines, subunit vaccines such as influenza and pneumococcal vaccines, toxoids such as diphtheria and tetanus toxoid, and recombinant vaccines such as hepatitis B, human papillomavirus [HPV], and influenza  

Inactivated Vaccines Market Dynamics

Drivers

• Increasing Clinical Research Activities

The wide introduction of new inactivated vaccines after completion of clinical studies are anticipated to increase the growth of the inactivated vaccines market during the forecast period. For instance, Merck’s investigational inactivated varicella zoster virus vaccine (V212) specified that a decrease in the occurrence of herpes zoster case by an estimated 64% in immunocompromised subjects in the first phase 3 trial in 2017. Clinical studies also showed that V212 lessens the incidence of herpes zoster pain by about 69.5%. Furthermore, V212 showed 83.7% reduction in the prevalence of post herpetic neuralgia. Furthermore, Bharat Biotech launched JENVAC vaccine to offer long-term protection and immunogenicity against Japanese encephalitis in 2013. The primary benefit of this novel fully indigenous inactivated vaccine is that it can be administered during disease epidemics, since it is an inactivated vaccine and is highly purified. Thus, this boosts the market growth.

Opportunities

• Increasing Prevalence of Infectious Diseases

Increasing occurrence of numerous viral and bacterial diseases globally have increased the demand for inactivated vaccines, which in turn will boost the market growth. For instance, as per the records of the World Health Organization (WHO) report in 2018, annual epidemics because of influenza were expected to result in about 3 to 5 million cases of extreme illness and around 290,000 to 650,000 deaths. Furthermore, WHO 2018 report also signified that about 21 million cases and 222,000 typhoid-related deaths occur annually globally. Thus, this factor boost the market growth.

• Growing Government Support

The increasing government support towards the growth of healthcare sector is most likely to increase the growth of inactivated vaccine market revenue in this region. For instance, the U.S. Department of Health and Human Services shifted funds of about US$ 81 million from other projects to continue developing vaccines to fight against Zika virus in 2016. Thus, this factor in creases the market growth.

Restraints/Challenges

• High Cost of Treatment

The increasing expenditure associated with the manufacturing and delivering the vaccines hamper the market growth. These vaccines require immense expenditure and the cost is also high and thus people in the major developing and underdeveloped countries, cannot adopt for the vaccines. This impedes the market growth.

This inactivated vaccines market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the inactivated vaccines market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Inactivated Vaccines Market Scope

The inactivated vaccines market is segmented on the basis of product, route of administration, method of activation, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• Viral
• Bacterial
• Others

Route of Administration

• Oral
• Subcutaneous
• Others

Method of Activation

• Solvent Detergent
• Radiation
• pH Concentration
• Heat Inactivation
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Inactivated Vaccines Market Regional Analysis/Insights

The inactivated vaccines market is analyzed and market size insights and trends are provided by product, route of administration, method of activation, end-users and distribution channel as referenced above.

The major countries covered in the inactivated vaccines market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America has been witnessing a positive growth for inactivated vaccines market throughout the forecasted period because of the focus of major market players on novel technology or formulation of existing drugs. A rise in infectious illness and viral infection instances, upgraded health service, and an improvement of health consciousness among private agencies and government are the major drivers boosting the market growth in this region throughout the forecast period 2023-2030.

Asia-Pacific dominates the market because of the high incidence cases of infectious diseases and number of generic drugs. Rapidly growing population combined with urbanization, technical advances and infrastructural developments in the medical sector, an uptick in government expenditure to increase the immunization programs, and sprouting health awareness through NGOs' campaigns are some of the forces prompting the regional market growth.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Inactivated Vaccines Market Share Analysis

The inactivated vaccines market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to inactivated vaccines market

Key players operating in the inactivated vaccines market include:

• GSK plc (U.K.)
• Novartis AG (Switzerland)
• Mylan N.V. (U.S.)
• Sanofi (France)
• Boehringer Ingelheim International GmbH. (Germany)
• Merck & Co., Inc. (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Bristol-Myers Squibb Company (U.S.)
• Bharat Biotech (India)
• Serum Institute of India Pvt. Ltd (India)
• Valneva SE (France)
• Nórdico bávaro (Dinamarca)
• INOVIO Pharmaceuticals (Estados Unidos)
• Novavax (Estados Unidos)
• DAIICHI SANKYO COMPANY, LIMITED (Japón)
• Mitsubishi Chemical Group Corporation (Japón)

SKU-52559